脊髓或背根神经节刺激治疗慢性疼痛的长期取出风险
该回顾性分析纳入2012至2022年在Sahlgrenska大学医院植入脊髓刺激(SCS)或背根神经节(DRG)刺激系统的400例慢性疼痛患者,发现任何原因的累积取出风险在3、5、10年分别为17%、23%、38%,因疼痛缓解减退的取出风险分别为10%、14%、23%,多变量分析未发现其他预测因素。
要点
- SCS和DRG刺激长期取出风险高,10年任何原因取出风险达38%。
- 因疼痛缓解减退的10年取出风险为23%,需关注长期疗效。
- 不同制造商间5年取出风险无显著差异,但因疼痛缓解减退的取出风险美敦力(尤其老款SCS)和DRG刺激更高。
核心结论
- SCS和DRG刺激治疗慢性疼痛的长期取出风险仍较高。
- 不同制造商间因疼痛缓解减退的取出风险存在差异,提示技术演进的重要性。
研究设计与样本
- 回顾性分析纳入2012年1月至2022年12月在Sahlgrenska大学医院植入SCS或DRG刺激系统的400例患者。
- 通过病历回顾获取患者特征、取出率及取出原因。
主要发现
- 任何原因累积取出风险在3、5、10年分别为17%、23%、38%。
- 因疼痛缓解减退的取出风险在3、5、10年分别为10%、14%、23%。
- Kaplan-Meier分析显示不同制造商5年取出风险无统计学显著差异。
- 多变量Cox回归分析中,任何原因取出风险无差异,但因疼痛缓解减退的取出风险美敦力(尤其老款SCS)和DRG刺激更高。
- 未发现其他取出预测因素。
临床怎么用
- 临床应重视SCS和DRG刺激的长期随访,关注疼痛缓解减退导致的取出风险。
- 患者选择需更严格,并考虑设备软硬件技术更新以延长使用寿命。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate long-term explantation risks and causes for the explantation of neuromodulation devices for the treatment of chronic pain from different manufacturers. METHODS: This retrospective analysis included patients implanted with a system for spinal cord stimulation (SCS) or dorsal root ganglion (DRG) stimulation at Sahlgrenska University Hospital between January 2012 and December 2022. Patient characteristics, explantation rates and causes for explantation were obtained by reviewing medical records. RESULTS: In total, 400 patients were included in the study. Including all manufacturers, the cumulative explantation risk for any reason was 17%, 23% and 38% at 3, 5 and 10 years, respectively. Explantation risk due to diminished pain relief at the same intervals was 10%, 14% and 23%. A subgroup comparison of 5-year explantation risk using Kaplan-Meier analysis did not show a statistically significant difference between the manufacturers. In multivariable Cox regression analyses, there was no difference in explantation risk for any reason, but for explantation due to diminished pain relief, a higher risk was noted for Medtronic (preferably older types of SCS devices) and DRG stimulation. No other predictive factor for explantation was found. CONCLUSIONS: Although SCS and DRG stimulation are well-established and safe treatments for chronic pain, the long-term explantation risk remains high. The difference between manufacturers highlights the importance of technological evolution for improving therapy outcomes. Increased stringency in patient selection and follow-up strategies, as well as further development of device hardware and software technology for increased longevity, could possibly reduce long-term explantation risks.
引用
- Gatzinsky K, Brink B, Eyglóardóttir KL, et al. Long-term explantation risk in patients with chronic pain treated with spinal cord or dorsal root ganglion stimulation. Reg Anesth Pain Med. 2025. PMID: 39084704. doi:10.1136/rapm-2024-105719
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。